Obesity and renal disease: Not all fat is created equal and not all obesity is harmful to the kidneys

Nephrology Dialysis Transplantation

Volumn 31, Issue 5, 2016, Pages 726-730

  Stefan, Norbert ^a,b,c   Artunc, Ferruh ^a   Heyne, Nils ^a   Machann, Jürgen ^b,c   Schleicher, Erwin D ^a,b,c   Häring, Hans Ulrich ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

chronic kidney disease; insulin resistance; metabolically healthy obesity; non alcoholic fatty liver disease; subclinical inflammation

Indexed keywords

FETUIN A; INSULIN;

BODY FAT; CHRONIC KIDNEY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PERIVASCULAR FAT; PRIORITY JOURNAL; PROTEIN METABOLISM; RENAL SINUS FAT; REVIEW; RISK ASSESSMENT; RISK FACTOR; ADIPOSE TISSUE; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY;

EID: 84965163560     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu081     Document Type: Review

References (48)

1. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567
2. Hu FB,Willett WC, Li T et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351: 2694-2703
3. Malik VS,Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013; 9: 13-27
4. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
5. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169
6. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
7. Ejerblad E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702
8. Pinto-Sietsma SJ, Navis G, JanssenWMet al. Acentral body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41: 733-741
9. Kanasaki K, Kitada M, Kanasaki M et al. the biological consequence of obesity on the kidney. Nephrol Dial Transplant 2013; 28(Suppl. 4): iv1-iv7
10. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26: 59-62
11. Cirillo M, Senigalliesi L, LaurenziMet al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158: 1933-1939
12. Tozawa M, Iseki K, Iseki C et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956-962
13. Chandie Shaw PK, Berger SP, Mallat M et al. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian subjects. Diabetes Care 2007; 30: 1840-1844
14. Nerpin E, Risérus U, Ingelsson E et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008; 31: 1550-1555
15. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806
16. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013; 339: 172-177
17. Adamczak M, Wiecek A. the adipose tissue as an endocrine organ. Semin Nephrol 2013; 33: 2-13
18. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118: 1645-1656
19. Wolf G, Hamann A, Han DC et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int 1999; 56: 860-872
20. Stefan N, Häring HU, Hu FB et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013; 1: 152-162
21. Stefan N, Kantartzis K, Machann J et al. Global trends in body-mass index. Lancet 2011; 377: 1917
22. Stefan N, Kantartzis K,Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
23. Appleton SL, Seaborn CJ, Visvanathan R et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: A cohort study. Diabetes Care 2013; 36: 2388-2394
24. Klöting N, Fasshauer M, Dietrich A et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506-E515
25. Kantartzis K, Machann J, Schick F et al. the impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 2010; 53: 882-889
26. Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-960
27. Stefan N, Häring HU. the role of hepatokines in metabolism. Nat Rev Endocrinol 2013; 9: 144-152
28. Stefan N, Hennige AM, StaigerHet al. α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006; 29: 853-857
29. Haukeland JW, DahlTB, YndestadAet al. FetuinAin nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 2012; 166: 503-510
30. Stefan N, Häring HU. the metabolically benign and malignant fatty liver. Diabetes 2011; 60: 2011-2017
31. Lehmann R, Franken H, Dammeier S et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013; 36: 2331-2338
32. Auberger P, Falquerho L, Contreres JO et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989; 58: 631-640
33. Hennige AM, Staiger H, Wicke C et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 2008; 3: e1765
34. Stefan N, Fritsche A,Weikert C et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767
35. Ix JH, Wassel CL, Kanaya AM et al., Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008; 300: 182-188
36. Weikert C, Stefan N, SchulzeMBet al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118: 2555-2562
37. Fisher E, Stefan N, Saar K et al. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPICPotsdam study. Circ Cardiovasc Genet 2009; 2: 607-613
38. Pal D, Dasgupta S, Kundu R et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285
39. Heinrichsdorff J, Olefsky JM. Fetuin-A: The missing link in lipid-induced inflammation. Nat Med 2012; 18: 1182-1183
40. Stefan N, Häring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 2013; 19: 394-395
41. Schafer C, Heiss A, Schwarz A et al. the serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366
42. Li M, Xu M, Bi Y et al. Association between higher serum fetuin-A concentrations and abnormal albuminuria in middle-aged and elderly Chinese with normal glucose tolerance. Diabetes Care 2010; 33: 2462-2464
43. Siegel-Axel DI, Ullrich S, Stefan N et al. Fetuin-A influences vascular cell growth and production of proinflammatory and angiogenic proteins by human perivascular fat cells. Diabetologia. Epub ahead of print 4 February 2014
44. Yudkin JS, Eringa E, Stehouwer CD. 'Vasocrine' signalling from perivascular fat: A mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-1820
45. Rittig K, Staib K, Machann J et al. Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia 2008; 51: 2093-2099
46. Wagner R, Machann J, Lehmann R et al. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia 2012; 55: 2054-2058
47. Foster MC, Hwang SJ, Porter SA et al. Fatty kidney, hypertension, and chronic kidney disease: The Framingham Heart Study. Hypertension 2011; 58: 784-790
48. Rittig K, Dolderer JH, Balletshofer B et al. the secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia 2012; 55: 1514-1525